Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia
July 2003
in “Drug Development Research”
TLDR Fluridil promotes hair growth safely and effectively for androgenetic alopecia.
The paper discusses the development of fluridil, a topical suppressor of the androgen receptor for the treatment of androgenetic alopecia (AGA). Fluridil was found to be effective in promoting hair growth in a 12-month clinical study of male AGA patients, with no adverse side effects reported. The compound was designed to achieve rapid degradation into innocuous components, no systemic absorption from the scalp, and topical delivery to the dermal hair papilla. Fluridil was shown to be well-tolerated and safe in mice, with little potential for human hazard at the intended topical dose. The study suggests that fluridil may be a promising treatment for AGA.
View this study on onlinelibrary.wiley.com →
Cited in this study
research Towards a molecular understanding of hair loss and its treatment
Future hair loss treatments should aim to extend hair growth, reactivate resting follicles, reverse shrinkage, and possibly create new follicles, with gene therapy showing promise.
research Treatments for Androgenetic Alopecia and Alopecia Areata
Minoxidil and finasteride treat hair loss; more research needed for other options.
research Lack of effect of topical finasteride suggests an endocrine role for dihydrotestosterone
Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.
research Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships
Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.
research Treatment of Hair Loss
Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.
research Finasteride in the treatment of men with androgenetic alopecia
Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.
research Evaluation of RU58841 as an Anti-Androgen in Prostate PC3 Cells and a Topical Anti-Alopecia Agent in the Bald Scalp of Stumptailed Macaques
RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.
research A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice
research Inhibition of Hair Growth by Testosterone in the Presence of Dermal Papilla Cells from the Frontal Bald Scalp of the Postpubertal Stumptailed Macaque1
Testosterone can slow down hair growth when combined with certain cells from bald scalps, and this effect can be blocked by an androgen receptor blocker.
research Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course
Topical finasteride helps regrow hair and reduce balding without side effects.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
RU 58841 may treat acne, hair loss, and excessive hair growth.
Related
![Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.](/images/research/861159f1-7bd4-420c-a16b-4829458efe68/small/15592.jpg)
research Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
The compounds tested could potentially treat hair loss and alopecia.